NR4A1 and breast cancer: These results clearly highlighted the potential limitations in using random cutoff points when using Ki-67 as a prognostic marker in the evaluation of breast cancer; however, given the clear relationship of Ki-67 with DFS and OS in hormone receptor-positive patients, the authors suggest that there is clear value in using Ki-67 expression as a continuous variable reflecting the percentage of proliferating cells in the tumor.